The notion of pain as just a peripheral, or strictly stimulus-driven, phenomenon is over.
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists
New Hydrogel May Offer Promising Osteoarthritis Treatment
A new hydrogel that can be stretched and is self-healing might become an effective ligament repair option in osteoarthritis (OA).
Rheumatology Drug Updates
Information on new approvals and medication safety rheumatologists need to know
Rheumatology Drug Updates: Apremilast, Golimumab, and More
Information on new approvals and medication safety rheumatologists need to know
Drug Diversion Concerns on the Rise
Medications removed from legitimate supply channels can affect both physician and patient.
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
Advances in the rheumatology clinic are promising, two experts say.
American College of Rheumatology Leads Charge to Address Excessive Patient Cost Sharing
The ACR Government Affairs Committee has developed legislative language to limit commercial insurance plans’ cost-sharing requirements for medications in a specialty drug tier to the dollar amount applicable to drugs in the nonpreferred-brand drug tier.
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 123
- Next Page »